$36.620
-0.128 (-0.35%)終値時点
IMCR のニュース
IMCR のイベント
Immunocore Reports Q2 Revenue of $115.93M, Exceeds Expectations
Reports Q2 revenue $115.93M, consensus $110.37M. "The five-year overall survival data for KIMMTRAK underscores the lasting impact of our medicine for patients with metastatic uveal melanoma and reinforces our confidence in the potential of our platform," said Bahija Jallal, CEO of Immunocore. "With enrollment in our Phase 3 TEBE-AM trial nearing target completion and continued progress across our pipeline, we remain focused on our mission: delivering innovative transformative medicines to improve outcomes for patients with serious diseases."
Immunocore Updates Brenetafusp Clinical Trial Results
Immunocore announced updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma. The data is presented in a poster at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting. In the 66 patients treated with brenetafusp monotherapy, the median overall survival was 14.3 months with a landmark OS rate of 87% at 6 months and 57% at 12 months. The disease control rate was 52%, while the overall response rate was 12%. Multiple measures of clinical benefit were numerically higher for patients treated with the 160 mcg dose - despite worse baseline prognostic factors compared to those treated with 40 mcg. These data support selection of 160 mcg for the ongoing Phase 3 trial evaluating brenetafusp + nivolumab vs. standard nivolumab regimens in first-line advanced melanoma. The safety profile was similar at both doses. Brenetafusp was generally well tolerated, showing a predictable, mechanism-driven safety profile as monotherapy and in combination.
Immunocore Q1 Revenue at $106.68M, Below Consensus
Reports Q1 revenue $106.68M, consensus $107.08M. "We are proud to report another quarter of strong commercial performance, with KIMMTRAK generating $107 million in net revenues in Q1 2026," said Bahija Jallal, CEO of Immunocore. "The five-year overall survival (OS) data from our Phase 3 trial presented at AACR is a landmark moment. It is the longest OS follow-up ever reported in a randomized trial in metastatic uveal melanoma and underscores the long-term benefit KIMMTRAK delivers to patients. In parallel, we are executing with discipline across our pipeline."
Immunocore Kimmtrak Achieves 16% Five-Year Survival Rate
Immunocore announced that Kimmtrak five-year overall survival, OS, was presented in an oral session at the American Association for Cancer Research, AACR, 2026 meeting. This is the longest, prospective Phase 3 randomized trial in patients with unresectable or metastatic uveal melanoma - a disease with a very poor prognosis and a historical survival rate of less than 5% at 5 years. Kimmtrak doubled the likelihood of being alive at five years, with an OS for Kimmtrak of 16% versus 8% in the control arm. These results also represent the longest follow-up reported for any T cell engager in a solid tumor.
Immunocore Reports Q4 Revenue of $104.5M
Reports Q4 revenue $104.5M, consensus $107.77M. "With $400 million in KIMMTRAK sales and a diverse clinical portfolio, Immunocore had a productive year of growth and progress in 2025," said Bahija Jallal, CEO of Immunocore. "Our priority for 2026 is the clear execution of our clinical trials, particularly as we anticipate key data in oncology and begin our first trial in autoimmune disease. We remain focused on the long-term goal of developing medicines that can significantly improve patient lives."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。